Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kelly Sandberg

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
The American Journal of Gastroenterology|March 6, 2024
High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn's DiseaseDawn R Ebach, Traci W Jester, Joseph A Galanko, et al.
The American Journal of Gastroenterology|May 2, 2025
HLA DQA1*05 and Risk of Antitumor Necrosis Factor Treatment Failure and Anti-Drug Antibody Development in Children With Crohn's DiseaseJeremy Adler, Joseph A Galanko, Rana Ammoury, et al.
The American Journal of Gastroenterology|October 18, 2024
HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease: HLA DQA1*05 and Pediatric Crohn's DiseaseJeremy Adler, Joseph A Galanko, Rana Ammoury, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
The American Journal of Gastroenterology|March 6, 2024
High Body Mass Index and Response to Anti-Tumor Necrosis Factor Therapy in Pediatric Crohn's DiseaseDawn R Ebach, Traci W Jester, Joseph A Galanko, et al.
The American Journal of Gastroenterology|May 2, 2025
HLA DQA1*05 and Risk of Antitumor Necrosis Factor Treatment Failure and Anti-Drug Antibody Development in Children With Crohn's DiseaseJeremy Adler, Joseph A Galanko, Rana Ammoury, et al.
The American Journal of Gastroenterology|October 18, 2024
HLA DQA1*05 and risk of anti-TNF treatment failure and anti-drug antibody development in children with Crohn's Disease: HLA DQA1*05 and Pediatric Crohn's DiseaseJeremy Adler, Joseph A Galanko, Rana Ammoury, et al.
Pageof 2